doi: 10.5507/bp.2005.037.
Applications of new laboratory marker assays in neurological diagnoses - a pilot study
Affiliations
- PMID: 16601767
- DOI: 10.5507/bp.2005.037
Item in Clipboard
Applications of new laboratory marker assays in neurological diagnoses - a pilot study
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
2005 Dec.
Abstract
225 consecutive patients with different neurological diseases and 101 individuals as the control were examined between 2002-2004. Cystatin C, arginase-I, tau-protein and beta-amyloid were measured. Individuals with CNS inflammation had significantly lower Cystatin-C index (CSF/serum) values. There was no diagnostic significance of the Arginase-I assay in CSF was verified. The CSF tau-protein/beta-amyloid index was shown to be a sufficient efficacy for neurodegenerative disease diagnosis.
Similar articles
-
The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases.Neurol Sci. 2009 Feb;30(1):1-7. doi: 10.1007/s10072-008-0005-7. Epub 2009 Jan 20. Neurol Sci. 2009. PMID: 19153649 Clinical Trial.
-
Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.Neurosci Lett. 2020 Jan 10;715:134564. doi: 10.1016/j.neulet.2019.134564. Epub 2019 Nov 13. Neurosci Lett. 2020. PMID: 31733322
-
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.BMC Neurol. 2009 Dec 22;9:63. doi: 10.1186/1471-2377-9-63. BMC Neurol. 2009. PMID: 20028512 Free PMC article.
-
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26452984 Review.
-
Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.Curr Opin Psychiatry. 2015 Sep;28(5):402-9. doi: 10.1097/YCO.0000000000000179. Curr Opin Psychiatry. 2015. PMID: 26147615 Review.
Cited by
-
Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.J Neural Transm (Vienna). 2012 Mar;119(3):353-62. doi: 10.1007/s00702-011-0708-4. Epub 2011 Sep 4. J Neural Transm (Vienna). 2012. PMID: 21892760
-
CSF markers of neurodegeneration in Parkinson's disease.J Neural Transm (Vienna). 2010 Oct;117(10):1177-81. doi: 10.1007/s00702-010-0462-z. Epub 2010 Aug 21. J Neural Transm (Vienna). 2010. PMID: 20730548
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous